Vericel VCEL
NASDAQ VCEL
$40.19 -0.28 (-0.69%)
As of: Sep 4, 2026 · 3:59 PM EDT

Vericel (VCEL) Cash from Investing Activities (2010 - 2026)

Vericel (VCEL) posted Cash from Investing Activities of -$2.8 million for Q2 2026, up 32.87% sequentially from -$4.2 million in Q1 2026, and up 68.76% YoY from -$1.7 million in Q2 2025.

Analysis

Vericel (VCEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Vericel has reported Cash from Investing Activities for 17 years, with the latest figure at -$2.8 million in Q2 2026.

  • Quarterly Cash from Investing Activities rose 68.76% year-over-year to -$2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$26.8 million (up 55.38% YoY) and the FY2025 annual result came in at -$43.9 million, up 44.41% from the prior year.
  • Cash from Investing Activities advanced to -$2.8 million in Q2 2026 per VCEL's latest filing, from -$4.2 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $4.6 million in Q3 2023 and troughed at -$25.5 million in Q1 2024.
  • A 5-year average of -$9.4 million and a median of -$8.6 million in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 1252.73% in 2022, then surged 663.01% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$21.7 million in 2022, then soared by 62.78% to -$8.1 million in 2023, then sank by 81.14% to -$14.7 million in 2024, then retreated by 11.87% to -$16.4 million in 2025, then soared by 82.79% to -$2.8 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.8 million, -$4.2 million, and -$16.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Vericel 2.05 Bn 1.89 Bn 56.40 Mn -2.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.82 Mn
Mar 31, 2026 -4.20 Mn
Dec 31, 2025 -16.39 Mn
Sep 30, 2025 -3.38 Mn
Jun 30, 2025 -9.03 Mn
Mar 31, 2025 -15.14 Mn
Dec 31, 2024 -14.65 Mn
Sep 30, 2024 -21.21 Mn
Jun 30, 2024 -17.72 Mn
Mar 31, 2024 -25.45 Mn
Dec 31, 2023 -8.09 Mn
Sep 30, 2023 4.57 Mn
Jun 30, 2023 -2.41 Mn
Mar 31, 2023 2.80 Mn
Dec 31, 2022 -21.73 Mn
Sep 30, 2022 -811,000.00
Jun 30, 2022 -3.00 Mn
Mar 31, 2022 -10.67 Mn
Dec 31, 2021 1.89 Mn
Sep 30, 2021 -2.63 Mn